JY
CRXT

Jeff Yass’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Jeff Yass’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-22,543
Closed -$120K – 14311
2021
Q3 		$120K Buy
+22,543
New +$203K ﹤0.01% 11949

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $5.53B AUM 25.79% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Jeff Yass's CRXT Position: Q4 2021 in Review

Jeff Yass sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q4 2021, closing a stake of 22,543 shares — an estimated $120K sold.

Jeff Yass first reported a position in CRXT in Q3 2021 and held it in 1 quarter. The position peaked at $120K in Q3 2021. 12 funds tracked by Wall St. Rank hold CRXT as of Q4 2021.

  • Jeff Yass reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Jeff Yass sold 22,543 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q4 2021, an estimated $120K.
  • Jeff Yass first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Jeff Yass's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $120K in Q3 2021.
  • 12 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.